PIPELINE 000A20 MPR 0210 qxp 2 5 2010 10 by ProQuest


More Info
									000A20_MPR_0210.qxp      2/5/2010    10:49 AM    Page 1

                       Highlights of progress in drug development
               Cardiovascular                   CCX354 (from ChemoCentryx) a selective
   AMR101 (from Amarin) an ultra-pure           CCR1 chemokine receptor antagonist
   omega-3 form developed with ethyl ester      being evaluated for the treatment of
   of eicosapentaenoic acid being studied for   rheumatoid arthritis—Phase 2
   treating hypertriglyceridemia—Phase 3
                                                SBI-087 (from Trubion) a humanized
                      CNS                       Small Modular ImmunoPharmaceutical
   EVP-6124 (from EnVivo) a selective           (SMIP) protein therapeutically directed
   nicotinic acetylcholine receptor subtype     against the CD20 antigen being developed
   alpha-7 agonist being investigated for       for treating rheumatoid arthritis—Phase 2
   treating schizophrenia—Phase 2b
   Lurasidone (from Dainippon Sumitomo)         Phentermine + topiramate (Qnexa, from
   an atypical antipsychotic being assessed     Vivus) a controlled-release formulation of
   for the treatment of schizophrenia—          phentermine and topiramate being
   NDA submitted                                reviewed for treating obesity, including
                                                weight loss and maintenance of weight
   Retigabine (from Valeant) a neuronal         loss, in obese or overweight patients with
   potassium channel opener being reviewed      comorbidities such as hypertension,
   as an adjunctive treatment for partial-      type 2 diabetes, dyslipidemia or central
   onset seizures in adults—NDA accepted        adiposity—NDA submitted

         Dermatological disorders                               Oncology
   Apremilast (from Celgene) an orally          ADXS11-001 (from Advaxis) a therapeutic
To top